Universal Quantum partners with Open Quantum Institute to tackle endometriosis with new technology
Ella Day | July 29, 2025 | News story | Medical Communications, Research and Development | Open Quantum Institute, Pain, Reproductive health, UN Sustainable Development Goals, United Nations, Universal Quantum, endometriosis, women's health
Based in Brighton, UK, Universal Quantum has joined the Open Quantum Institute (OQI) to explore how quantum computing could revolutionise drug discovery and healthcare – starting with an ambitious new project targeting endometriosis.
Affecting 10% of women globally, endometriosis is a chronic and often debilitating condition that has long been underfunded and overlooked. Universal Quantum’s first project as part of OQI will explore how quantum simulations could accelerate the development of non-hormonal, shelf-stable treatments –especially for underserved populations in rural and low-resource settings.
As part of the project, Universal Quantum will collaborate with biomedicine and computational chemistry experts to simulate complex biomolecular systems, aiming to enhance how new therapeutics are discovered and tested.
Launched by GESDA in collaboration with the UN’s International Telecommunications Union and CERN (European Organization for Nuclear Research), the OQI serves as a neutral platform for exploring quantum use cases aligned with the UN Sustainable Development Goals. Universal Quantum joins a growing network of academic, industry and institutional partners focused on ethical quantum innovation.
“This is a complex challenge that won’t be solved by quantum computing alone,” added Universal Quantum CEO Sebastian Weidt. “By working together, we can move closer to scientific breakthroughs that serve global needs.”
Ella Day
29/7/25
Related Content
The Problem of Endometriosis in the UK
When did we decide it was an acceptable condition of womanhood in the UK to …
Theramex receives recommendation for YSELTY in Scotland
Theramex, a dedicated women’s health company, have announced that the Scottish Medicines Consortium (SMC) have …
Janssen’s study for nipocalimab as indicated for EOS-HDFN published in The New England Journal of Medicine
Johnson & Johnson company Janssen has announced that the results from its phase 2 trial …
